A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Inclusion Criteria:

• Male or female, 18 to 75 years of age

• Body mass index (BMI) ≥25.0 kg/m^2

• Have a diagnosis of Type 2 Diabetes Mellitus (T2DM) according to the World HealthOrganization classification or other locally applicable standards

• Have an HbA1c ≥7% and ≤10.5%

• Management of T2DM with diet and exercise alone, metformin, or a sodium-glucosecotransporter-2 (SGLT-2) inhibitor, as monotherapy or in combination, per approvedlocal label

• At least one self-reported unsuccessful diet/exercise effort to lose body weight

Exclusion Criteria:

• Have Type 1 Diabetes Mellitus (T1DM), history of ketosis or hyperosmolar state/coma,or any other types of diabetes except T2DM

• Have had 1 or more episodes of Level 3 hypoglycemia or have had hypoglycemiaunawareness within 3 months prior to screening

• Have history or presence of proliferative diabetic retinopathy, diabetic macularedema, or non-proliferative diabetic retinopathy that requires acute treatment

• Have evidence of clinically significant autonomic neuropathy (symptoms may includeresting tachycardia, orthostatic hypotension, or diabetic diarrhea)

• Had treatment with any oral antihyperglycemic medications, with the exception ofmetformin or SGLT-2 inhibitors, within 3 months prior to screening or plannedconcurrent treatment with these medications during the study

• Had treatment with injectable antihyperglycemic medication, with the exception ofshort-term insulin, within 6 months prior to screening or planned concurrenttreatment with these medications during the study

• Self-reported body weight change of >5 kg within 3 months before screening

• Any unbalanced/extreme diets, such as very low calorie, low carbohydrate, very highprotein, ketogenic, or intermittent diets, within 3 months of the screening visit,or plan to be on such diets during the study

• Current or recent use of any treatment that promotes weight loss or glucosemetabolism

• Current or recent use of treatment that may cause weight gain

• Prior or planned surgical treatment or procedure for obesity, except for liposuctionor abdominoplasty if performed >1 year prior to screening. Participants with ahistory of devices, such as LAP-BAND® or intragastric balloon, are permitted, ifdevices were removed >1 year prior to screening.

• History of clinically significant or active gastric emptying abnormality (e.g.,severe gastroparesis or gastric outlet obstruction, intestinal obstruction), orchronic use of medications that directly affect GI motility

• History of chronic pancreatitis or acute pancreatitis or have signs and symptoms ofacute pancreatitis at screening

• Have obesity induced by other endocrinologic disorders (e.g., Cushing syndrome) ordiagnosed monogenetic or syndromic forms of obesity

• History or diagnosis of significant active or unstable major depressive disorder orany history/diagnosis of other severe psychiatric conditions (e.g., schizophrenia;bipolar disorder; other serious mood disorder or anxiety disorder, or hyperactivitydisorder) within the last year before screening

• History of any hematologic conditions that may interfere with HbA1c measurement (e.g., hemolytic anemias, sickle cell disease, other hemoglobinopathies)

• Family or personal history of medullary thyroid carcinoma

• Women who are pregnant, breastfeeding, or intend to become pregnant, or are ofchildbearing potential and not using a highly effective contraceptive method asrequired per protocol